Title: Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis:
post-marketing surveillance study
Version: 3 Date: 31 May 2024
Reviewer's report:
I think this is a valuable paper that sheds light on the actual clinical practice of tofacitinib.
However, the figures and tables have not been properly submitted and are not worthy of peer
review (Fig. 3 and Fig. 4).Please correct and resubmit promptly.
Please also mention the following points:
##The frequency of patients with a history of biologic therapy is low. I believe that the
international standard for the indication of JAK inhibitors is that patients have failed to respond
to at least one biologic agent. Please explain the reason for this and the specific background
of Korea.
##Please indicate whether there was a difference in the remission maintenance dose of
tofacutinib and the incidence of adverse events.
##The incidence of shingles seems to be low. Is there any reason for this, such as a high
vaccination rate?
Title: Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis:
post-marketing surveillance study
Version: 3 Date: 31 May 2024
Reviewer's report:
I think this is a valuable paper that sheds light on the actual clinical practice of tofacitinib.
However, the figures and tables have not been properly submitted and are not worthy of peer
review (Fig. 3 and Fig. 4).Please correct and resubmit promptly.
Please also mention the following points:
##The frequency of patients with a history of biologic therapy is low. I believe that the
international standard for the indication of JAK inhibitors is that patients have failed to respond
to at least one biologic agent. Please explain the reason for this and the specific background
of Korea.
##Please indicate whether there was a difference in the remission maintenance dose of
tofacutinib and the incidence of adverse events.
##The incidence of shingles seems to be low. Is there any reason for this, such as a high
vaccination rate?
Please review this paper.
user
Title: Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis:
post-marketing surveillance study
Version: 3 Date: 31 May 2024
Reviewer's report:
I think this is a valuable paper that sheds light on the actual clinical practice of tofacitinib.
However, the figures and tables have not been properly submitted and are not worthy of peer
review (Fig. 3 and Fig. 4).Please correct and resubmit promptly.
Please also mention the following points:
##The frequency of patients with a history of biologic therapy is low. I believe that the
international standard for the indication of JAK inhibitors is that patients have failed to respond
to at least one biologic agent. Please explain the reason for this and the specific background
of Korea.
##Please indicate whether there was a difference in the remission maintenance dose of
tofacutinib and the incidence of adverse events.
##The incidence of shingles seems to be low. Is there any reason for this, such as a high
vaccination rate?
assistant